Sera Prognostics (SERA) Competitors $1.92 -0.20 (-9.43%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.09 (+4.43%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SERA vs. VMD, AIRS, TOI, EUDA, DCGO, CORBF, XGN, QIPT, BMGL, and ATPCShould you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Viemed Healthcare (VMD), AirSculpt Technologies (AIRS), Oncology Institute (TOI), EUDA Health (EUDA), DocGo (DCGO), Global Cord Blood (CORBF), Exagen (XGN), Quipt Home Medical (QIPT), Basel Medical Group (BMGL), and Agape ATP (ATPC). These companies are all part of the "healthcare" industry. Sera Prognostics vs. Viemed Healthcare AirSculpt Technologies Oncology Institute EUDA Health DocGo Global Cord Blood Exagen Quipt Home Medical Basel Medical Group Agape ATP Sera Prognostics (NASDAQ:SERA) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Do institutionals and insiders have more ownership in SERA or VMD? 54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 13.5% of Sera Prognostics shares are owned by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor SERA or VMD? Sera Prognostics received 7 more outperform votes than Viemed Healthcare when rated by MarketBeat users. However, 42.86% of users gave Viemed Healthcare an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformSera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Viemed HealthcareOutperform Votes342.86% Underperform Votes457.14% Is SERA or VMD more profitable? Viemed Healthcare has a net margin of 4.87% compared to Sera Prognostics' net margin of 0.00%. Viemed Healthcare's return on equity of 8.72% beat Sera Prognostics' return on equity.Company Net Margins Return on Equity Return on Assets Sera PrognosticsN/A -51.73% -36.94% Viemed Healthcare 4.87%8.72%6.48% Which has stronger earnings and valuation, SERA or VMD? Viemed Healthcare has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSera Prognostics$115K699.41-$36.24M-$0.94-2.27Viemed Healthcare$232.79M1.14$10.24M$0.3022.43 Does the media favor SERA or VMD? In the previous week, Sera Prognostics and Sera Prognostics both had 2 articles in the media. Viemed Healthcare's average media sentiment score of 1.11 beat Sera Prognostics' score of 1.02 indicating that Viemed Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viemed Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SERA or VMD? Sera Prognostics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. SummaryViemed Healthcare beats Sera Prognostics on 12 of the 14 factors compared between the two stocks. Get Sera Prognostics News Delivered to You Automatically Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SERA vs. The Competition Export to ExcelMetricSera PrognosticsMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.01M$3.00B$5.42B$8.48BDividend YieldN/A31.24%5.22%4.11%P/E Ratio-2.2513.2326.7820.05Price / Sales699.41164.59395.49116.44Price / CashN/A57.5638.2534.62Price / Book0.974.316.874.61Net Income-$36.24M-$22.21M$3.22B$248.19M7 Day Performance-5.11%3.62%5.69%2.56%1 Month Performance-37.02%7.44%12.66%16.18%1 Year Performance-74.37%4.26%18.01%8.16% Sera Prognostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SERASera Prognostics1.2261 of 5 stars$1.92-9.4%N/A-74.8%$72.33M$115,000.00-1.94120Positive NewsEarnings ReportHigh Trading VolumeVMDViemed Healthcare2.3448 of 5 stars$6.51+3.0%N/A-4.2%$257.30M$224.26M24.11630Positive NewsHigh Trading VolumeAIRSAirSculpt Technologies0.4197 of 5 stars$3.31+10.7%$3.75+13.3%-11.6%$194.56M$172.10M-23.64240Gap UpHigh Trading VolumeTOIOncology Institute2.2527 of 5 stars$2.55-8.9%N/A+355.7%$192.68M$393.41M-3.27660Earnings ReportGap UpEUDAEUDA HealthN/A$4.07+4.9%N/A+67.2%$151.21M$4.01M0.002DCGODocGo3.6871 of 5 stars$1.45+3.2%$3.56+146.4%-54.3%$147.37M$520.50M5.162,920High Trading VolumeCORBFGlobal Cord BloodN/A$1.05-3.7%N/A-56.0%$127.63M$196.12M0.001,200XGNExagen4.5307 of 5 stars$5.77+1.1%$7.50+30.0%+218.7%$103.87M$56.72M-6.14220Analyst RevisionQIPTQuipt Home Medical1.5576 of 5 stars$2.13-2.3%$6.25+193.4%-33.7%$91.78M$244.72M-12.53800News CoverageBMGLBasel Medical GroupN/A$4.70-1.7%N/AN/A$86.74M$10.05M0.0036News CoverageGap DownHigh Trading VolumeATPCAgape ATP0.4258 of 5 stars$1.65+5.8%N/A-57.0%$82.51M$1.32M-2.2640Earnings Report Related Companies and Tools Related Companies VMD Competitors AIRS Competitors TOI Competitors EUDA Competitors DCGO Competitors CORBF Competitors XGN Competitors QIPT Competitors BMGL Competitors ATPC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SERA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
